Results from 32 Studies Highlight the INTERCEPT Blood System's Ability to Improve the Safety of Donated Blood by Inactivating Viruses, Bacteria, Protozoa and Leukocytes
CONCORD, Calif., Jun 09, 2008 (BUSINESS WIRE) -- Cerus Corporation (NASDAQ:CERS) announced today results from 32 studies on the INTERCEPT Blood System presented at the International Congress of the International Society of Blood Transfusion in Macao SAR, China. Study outcomes highlight clinical experience implementing the INTERCEPT Blood System for platelets and plasma into routine practice. Others demonstrate INTERCEPT's utility in the inactivation of current and emerging pathogens, such as malaria and avian influenza, in donated blood. The safety and efficacy of the INTERCEPT Blood System are also highlighted in results from a multi-year hemovigilence surveillance program and in a study of patients with a severe congenital bleeding disorder undergoing major surgery.
"The clinical outcomes from these studies further support the broad application of the INTERCEPT Blood System to increase blood safety and improve results for patients who require blood transfusions," said Laurence Corash, M.D., senior vice president and chief medical officer at Cerus Corporation. "More than 150,000 INTERCEPT Blood System disposable kits have been shipped to date to more than 60 sites in 20 countries, with mounting evidence for continued broader adoption of our pathogen inactivation technology."
CONCORD, Calif., Jun 09, 2008 (BUSINESS WIRE) -- Cerus Corporation (NASDAQ:CERS) announced today results from 32 studies on the INTERCEPT Blood System presented at the International Congress of the International Society of Blood Transfusion in Macao SAR, China. Study outcomes highlight clinical experience implementing the INTERCEPT Blood System for platelets and plasma into routine practice. Others demonstrate INTERCEPT's utility in the inactivation of current and emerging pathogens, such as malaria and avian influenza, in donated blood. The safety and efficacy of the INTERCEPT Blood System are also highlighted in results from a multi-year hemovigilence surveillance program and in a study of patients with a severe congenital bleeding disorder undergoing major surgery.
"The clinical outcomes from these studies further support the broad application of the INTERCEPT Blood System to increase blood safety and improve results for patients who require blood transfusions," said Laurence Corash, M.D., senior vice president and chief medical officer at Cerus Corporation. "More than 150,000 INTERCEPT Blood System disposable kits have been shipped to date to more than 60 sites in 20 countries, with mounting evidence for continued broader adoption of our pathogen inactivation technology."
No comments:
Post a Comment